Tumor Neovasculature-Targeted APRPG-PEG-PDLLA/MPEG-PDLLA Mixed Micelle Loading Combretastatin A-4 for Breast Cancer...

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Breast cancer remains a leading cause of death in women worldwide.
• Targeting tumor neovasculature offers a promising strategy for breast cancer treatment.
• Vascular disrupting agents like combretastatin A-4 (CA-4) show potential but require effective delivery systems.

Purpose of the Study:

• To develop and characterize combretastatin A-4 (CA-4) loaded peptide-modified mixed micelles for targeted breast cancer therapy.
• To evaluate the efficacy of these novel micelles in vitro and in vivo.
• To assess the potential of the developed system for improving breast cancer treatment outcomes.

Main Methods:

• Synthesis of Ala-Pro-Arg-Pro-Gly (APRPG) modified PEG-PDLLA polymer.
• Preparation of APRPG-PEG-PDLLA/MPEG-PDLLA mixed micelles using thin-film hydration.
• Characterization of micelles (particle size, zeta potential, morphology, drug loading, encapsulation efficiency).
• In vitro drug release, cytotoxicity, and cellular uptake studies.
• In vivo studies including imaging, biodistribution, anti-angiogenesis assay in zebrafish, and tumor growth inhibition in a 4T1 breast cancer model.

Main Results:

• Successfully synthesized and characterized APRPG-modified mixed micelles.
• Demonstrated sustained release of CA-4 and confirmed safety and potency of encapsulated drug.
• Showed enhanced cellular uptake and significant tumor site accumulation in vivo.
• Inhibited embryonic angiogenesis and significantly suppressed tumor growth in the 4T1 breast cancer model.
• Optimized micelle formulation achieved efficient drug loading and encapsulation.

Conclusions:

• Combretastatin A-4 (CA-4) loaded APRPG-PEG-PDLLA/MPEG-PDLLA mixed micelles are effective drug carriers for breast cancer therapy.
• The peptide modification enhances tumor targeting and accumulation, leading to significant tumor growth inhibition.
• This novel nanocarrier system holds great potential for improving breast cancer treatment by targeting tumor neovasculature.